{"schema_version":"secwatch.filing_event.v1","accession":"0001438533-26-000032","form_type":"8-K","ticker":"TVTX","cik":"0001438533","company_name":"Travere Therapeutics, Inc.","filed_at":"2026-04-14T23:59:59+00:00","discovered_at":"2026-05-14T18:02:32.294086+00:00","generated_at":"2026-05-15T06:21:54.928016+00:00","sec_items":["8.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"FDA approves Travere's FILSPARI for FSGS without nephrotic syndrome, expanding label beyond IgAN","bullets":["FDA approved FILSPARI (sparsentan) for FSGS without nephrotic syndrome in patients aged 8+, second indication.","Addressable U.S. population estimated >30,000 individuals with FSGS without nephrotic syndrome.","Phase 3 DUPLEX: 48% proteinuria reduction in non-nephrotic patients vs 27% irbesartan (p=0.0075).","eGFR benefit: treatment difference 1.1 mL/min/1.73m2 at Week 108 favoring FILSPARI.","Safety profile comparable to irbesartan, consistent with prior programs."],"urls":{"canonical":"https://secwatch.observer/filing/0001438533-26-000032","json":"https://secwatch.observer/filing/0001438533-26-000032.json","markdown":"https://secwatch.observer/filing/0001438533-26-000032.md","text":"https://secwatch.observer/filing/0001438533-26-000032.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1438533/000143853326000032/0001438533-26-000032-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1438533/000143853326000032/tvtx-20260413.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T06:21:54.928016+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}